PKR induces TGF-β and limits oncolytic immune therapy.

Bangxing HongUpasana SahuMatthew P MullarkeyEvan HongGuangsheng PeiYuanqing YanYoshihiro OtaniYeshavanth Banasavadi-SiddegowdaHuihui FanZhong-Ming ZhaoJianhua YuMichael A CaligiuriBalveen Kaur

Published in: Journal for immunotherapy of cancer (2023)

Thus, PKR represents the Achilles heel of oHSV therapy, restricting both viral replication and antitumor immunity, and an oncolytic virus that can target this pathway significantly improves response to virotherapy.

Keyphrases

sars cov
stem cells
mesenchymal stem cells
bone marrow
signaling pathway
cell therapy
disease virus